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The cellular and molecular 
components of sodium taste
Chandrashekar et al., Nature 2010; 464: 297–301; doi:10.1038/
nature08783
Sodium is the most abundant cation of the extracellular 
fluid, and the volume of this fluid is determined mainly by 
its sodium content. Unsurprisingly, animals have evolved a 
salt-sensing system that can be driven to satisfy ‘salt appetite’ 
(or the ‘hunger for salt,’ in Derek Denton’s felicitous phrase). 
Unfortunately, for modern humans in affluent societies, the 
taste for salt has resulted in excessive Na+ consumption and a 
dramatic increase in the average arterial pressure. In mice, the 
behaviorally ‘attractive’ salt-taste pathway has the following 
characteristics: it is activated by low concentrations of NaCl 
(10 mM), is highly selective for sodium, and is blocked by 
lingual application of amiloride, an inhibitor of the epithelial 
sodium channel (ENaC). The effect of amiloride in humans 
has been less clear, however. Interestingly, in contrast to the 
‘attractive’ salt pathway, very high concentrations of sodium 
in food elicit an adverse response. To determine whether the 
physiological and behavioral responses to sodium are medi-
ated by the same or separate taste-receptor cells (TRCs), 
Chandrashekar et al. developed a preparation that allowed 
functional imaging of TRCs in response to salt. They found 
that, in contrast to high concentrations of NaCl, low concen-
trations activated a completely separate population of TRCs, 
which did not respond to non-sodium salts and had their 
responses blocked by amiloride. Hence, there are two anatom-
ically distinct salt-sensing TRCs, one of which is activated by 
low concentrations of NaCl and is highly selective for sodium 
salts. To examine the role of ENaCs in this taste system, the 
authors used a floxed ENaCα conditional knockout strategy, 
using the cytokeratin 19 gene (a marker for all TRCs) to drive 
the expression of Cre recombinase. ENaCα knockouts had a 
complete loss of the responses to low concentrations of NaCl 
but retained all responses to non-sodium salts, indicating that 
taste responses to salts are mediated by genetically separable 
components. In an elegant experiment, the authors found that 
after diuretic-induced Na+ depletion, control animals had an 
extraordinary appetite for sodium (Figure), whereas ENaCα 
knockout mice showed no significant attraction to salt. Using 
TRC-specific markers, they also found that ENaCα-expressing 
cells were distinct from sweet, bitter, or umami TRCs.
Hence, these experiments confirm the long-held suspicion 
that ENaC is the sodium taste receptor and demonstrate that 
sodium-sensing TRCs are anatomically and functionally dis-
tinct TRCs. Finally, this well-designed study suggests that 
the conflicting literature on the effect of amiloride on human 
salt taste is likely due to the difficulties in measuring human 
behavioral responses.
Juan Oliver
A new mechanism for Na+  
in the collecting duct
Leviel et al., J Clin Invest 2010; 120: 1627–1635; doi:10.1172/JCI40145
The fraction of filtered sodium that enters the connect-
ing tubule and collecting ducts can be reabsorbed via the 
aldosterone-regulated and amiloride-sensitive Na+ channel 
(ENaC). However, previous studies have shown that approxi-
mately half of the Na+ that is absorbed in the rat collecting 
duct is thiazide-sensitive and amiloride-insensitive, even 
though the expression of the target of thiazides, the Na-Cl 
cotransporter (NCC), is restricted to the distal convoluted 
tubule. To identify the transport system that accounts for this 
Na+ absorption, Leviel et al. used a variety of approaches in 
mice and found that their cortical collecting ducts (CCDs) 
had a thiazide-sensitive component of Na+ absorption that 
was ENaC-independent, appeared to be electroneutral, and 
did not facilitate K+ secretion. They next studied mice with 
a genetic disruption of Slc12a3, the gene encoding NCC 
(Ncc–/– mice); NaCl absorption in CCDs from Ncc–/– mice was 
amiloride-insensitive but was fully inhibited by hydrochloro-
thiazide (HCTZ) (Figure). Because in the CCD, Cl– absorption 
depends on the Cl–/HCO3
– exchanger pendrin, the authors 
postulated that the HCTZ-sensitive NaCl transport resulted 
from the coupling of pendrin-mediated Cl– reabsorption with 
Knockout of ENaCα in TRCs selectively abolishes the attractive taste of 
NaCl. After diuretic-induced Na+ depletion, ENaC-KO mice show little 
or no preference for NaCl solutions relative to water, whereas littermate 
controls exhibit very robust attractive responses.
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Effects of amiloride (amil) and HCTZ on Na+ transepithelial fluxes in CCDs 
isolated from wild-type (Ncc+/+) and Ncc–/– mice.
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H+- or HCO3
–-dependent Na+ transport. Functional stud-
ies suggested that Na+ uptake was driven by a Cl–/HCO3
– 
exchanger, and Leviel et al. focused on NDCBE (encoded 
by Slc4a8), which promotes the electroneutral exchange of 
one intracellular Cl– ion for one Na+ and two HCO3
– ions. 
Although this transporter is predominantly expressed in the 
brain and testis, NDCBE is also present in the kidney. Genera-
tion of mice with deletion of NDCBE (Ndcbe–/–) and charac-
terization of Na+ and Cl– transport in their CCDs showed that 
while amiloride-resistant NaCl absorption was detectable in 
CCDs from Na+-depleted wild-type mice, NaCl absorption in 
the presence of luminal amiloride was not different from zero 
in CCDs from Na+-depleted Ndcbe–/– mice, demonstrating 
that amiloride-resistant Na+ transport depends on NDCBE. 
In vitro experiments indicated that pendrin, but not NDCBE, 
could be inhibited by thiazides.
In sum, the work identifies a new mechanism of apical NaCl 
uptake in the collecting duct that results from parallel opera-
tion of two bicarbonate transporters: the Na+-driven Cl–/
HCO3
– exchanger NDCBE and the Na+-independent anion 
exchanger pendrin. The mechanism mediates net electro-
neutral thiazide-sensitive NaCl reabsorption in the CCD and 
explains why thiazides block a large fraction of Na+ absorp-
tion in the CCD. It may also explain why thiazides are better 
antihypertensives than other diuretics.
Juan Oliver
Systematic review: 
Erythropoiesis-stimulating 
agents in patients  
with chronic kidney disease
Palmer et al., Ann Intern Med advance online publication, 3 May 2010
Studies of anemia correction using erythropoiesis-stimulating 
agents (ESAs) in chronic kidney disease and end-stage renal 
disease (ESRD) have generated significant controversy and con-
fusion over quality and safety concerns. This meta-analysis by 
Palmer et al. combines the results of 27 trials conducted over a 
20-year span to further define the effects of anemia treatment 
using ESAs. Studies included randomized controlled trials of 
at least 3 months’ duration using erythropoietin-alfa, eryth-
ropoietin-beta, darbepoetin, or a continuous erythropoietin 
receptor activator, allocating patients to active treatment with 
one of these agents versus placebo, no treatment, or differ-
ent ESA doses to achieve a higher target. Over time, studies 
became larger, more rigorous in design, and more focused on 
cardiovascular end points. Overall, the authors concluded that 
the methodologic quality was not optimal among trials. Less 
than half of trials blinded patients, investigators, or outcome 
assessors to treatment assignment. Slightly fewer than half of 
trials analyzed with the intention-to-treat principle. Regarding 
outcomes, the risks for stroke (relative risk (RR) = 1.51, 95% 
confidence interval (CI) 1.03–2.21), vascular access thrombosis 
(RR = 1.33, 95% CI 1.16–1.53), and worsening hypertension 
(RR = 1.67, 95% CI 1.31–2.12) were all increased with a higher 
hemoglobin target, with no statistically significant difference 
in all-cause mortality (RR = 1.09, 95% CI 0.99–1.20), serious 
cardiovascular events (RR = 1.15, 95% CI 0.98–1.33), or pro-
gression to ESRD (RR = 1.08, 95% CI 0.97–1.20). The authors 
deemed the evidence describing quality of life in these studies 
to be of low quality, potentially biased due to selective reporting. 
Given that only two trials reported treatment effects on quality 
of life for all of the outcome domains and only one trial reported 
treatment effects on utility, the authors deferred to the results 
of the most recent treatment trial,1 summarizing that no differ-
ences in mean change in scores between groups for the energy 
or physical-function quality-of-life domains were demonstrated. 
Finally, a cumulative meta-analysis identified sufficient evidence 
describing the probable increased risk of death with a higher 
hemoglobin target when the first trial to include more than 
1000 patients was completed in 1998. With the enrollment of 
an additional 2670 patients in 2006, the increased risk for seri-
ous cardiovascular events was also evident.
The rigor with which this meta-analysis examines each of 
the individual patient outcomes is relevant, considering that 
our conclusions on the balance between risk and benefit for 
patients being treated for anemia have changed considerably 
since the first large trial of 1998. These estimates will contrib-
ute significantly to future trial design.
Lynda Szczech
1N Engl J Med 2009; 361: 2019–2032.
